References
- Lai -C-C, Shih T-P, Ko W-C, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
- Lai -C-C, Wang C-Y, Wang Y-H, et al. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020;55(4):105946.
- WHO. [cited 2021 Jun 4]. Available from:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.
- Chen PL, Lee NY, Cia CT, et al. A review of treatment of coronavirus disease 2019 (COVID-19): therapeutic repurposing and unmet clinical needs. Front Pharmacol. 2020;11:584956.
- Hsih WH, Cheng MY, Ho MW, et al. Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan. J Microbiol Immunol Infect. 2020;53:459–466.
- Huang YC, Lee PI, Hsueh PR. Evolving reporting criteria of COVID-19 in Taiwan during the epidemic. J Microbiol Immunol Infect. 2020;53:413–418.
- Krishnakumar B, Rana S. COVID 19 in INDIA: strategies to combat from combination threat of life and livelihood. J Microbiol Immunol Infect. 2020;53:389–391.
- Lee CY, Wang PS, Huang YD, et al. Evacuation of quarantine-qualified nationals from Wuhan for COVID-19 outbreak - Taiwan experience. J Microbiol Immunol Infect. 2020;53:392–393.
- Liao CH, Hung SC, Lee YT, et al. How do we decide to de-isolate COVID-19 patients? J Microbiol Immunol Infect. 2020;53:386–388.
- Yang C-J, Chen T-C, Chen Y-H. The preventive strategies of community hospital in the battle of fighting pandemic COVID-19 in Taiwan. J Microbiol Immunol Infect. 2020;53(3):381–383.
- Yen M-Y, Schwartz J, Chen S-Y, et al. Interrupting COVID-19 transmission by implementing enhanced traffic control bundling: implications for global prevention and control efforts. J Microbiol Immunol Infect. 2020;53(3):377–380.
- [cited 2021 Apr 9]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
- Baden LR, El SHM, Essink B, et al., Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 384(5): 403–4416. 2021.
- Keech C, Albert G, Cho I, et al. Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020;383(24):2320–2332.
- Polack FP, Thomas SJ, Kitchin N, et al., Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 383(27): 2603–2615. 2020.
- Walsh EE, Frenck RW Jr., Falsey AR, et al. Safety and immunogenicity of two RNA-Based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450.
- Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960.
- Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681.
- Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396(10267):1979–1993.
- Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.
- Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854.
- Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:682–694.
- [cited 2021 Apr 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT04505722
- Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021 Feb;NEJMoa2101765. 24. DOI:https://doi.org/10.1056/NEJMoa2101765.
- Abu Jabal K, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;(6):2100096. DOI: https://doi.org/10.2807/1560-7917.ES.2021.26.6.2100096.
- Samanovic MI, Cornelius AR, Wilson JP, et al. Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals. medRxiv. 2021 Feb. DOI: https://doi.org/10.1101/2021.02.07.21251311.
- Corbett KS, Edwards DK, Leist SR, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571.
- Blumenthal KG, Freeman EE, Saff RR, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021;84:1273–1277.
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396: 467–478.
- Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27:270–278.
- Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021 Mar 16. DOI:https://doi.org/10.1056/NEJMoa2102214.
- Mallapaty S, Callaway E. What scientists do and don’t know about the Oxford-AstraZeneca COVID vaccine. Nature. 2021 Apr;592:15–17.
- Tostanoski LH, Wegmann F, Martinot AJ, et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat Med. 2020;26:1694–1700.
- Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586:583–588.
- Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021 Jan;NEJMoa2034201. 13. doi:https://doi.org/10.1056/NEJMoa2034201
- [cited 2021 Mar 28]. Available from:https://clinicaltrials.gov/ct2/show/NCT04505722
- Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–897.
- Guebre-Xabier M, Patel N, Tian JH, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38:7892–7896.
- Tian JH, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12:372.
- [cited 2021 Mar 28] Available from: https://clinicaltrials.gov/ct2/show/record/NCT04611802?cond=Covid19&intr=NVX-CoV2373&phase=2&draw=1&rank=2
- [cited 2021 Apr 4]. Available from:https://clinicaltrials.gov/ct2/show/NCT04652102?term=CVnCoV&draw=2&rank=3
- Kuo TY, Lin MY, Coffman RL, et al. Development of CpG‑adjuvanted stable prefusion SARS‑CoV‑2 spike antigen as a subunit vaccine against COVID‑19. Sci Rep. 2020;10:20085.
- Hsieh SM, Liu WD, Huang YS, et al. First-in-human trial of a recombinant stabilized prefusion SARS-CoV-2 spike protein vaccine with adjuvant ofaluminum hydroxide and CpG 1018. medRxiv. 2021 April 6. DOI:https://doi.org/10.1101/2021.03.31.21254668.
- [cited 2021 Apr 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT04695652?term=MVC-COV1901&draw=2&rank=1 Accessed
- Guirakhoo F, Kuo L, Peng J, et al. A novel SARS-CoV-2 multitope protein/peptide vaccine candidate is highly immunogenic and prevents lung infection in an adeno associated virus human angiotensin-converting enzyme 2 (AAV hACE2) mouse model. bioRxiv. 2020 Nov 30. Available from: https://www.biorxiv.org/content/10.1101/2020.11.30.399154v1
- CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70:46–51.
- CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:125–129.
- Greinacher A, Thiele T, Warkentin TE, et al. Thrombocytic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021 Jun 3;384(22):2092-2101. DOI: https://doi.org/10.1056/NEJMoa2104840.
- Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after chAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 April 9;NEJMoa2104882. DOI:https://doi.org/10.1056/NEJMoa2104882.
- Saad-Roy CM, Morris SE, Metcalf CJE, et al. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science. 2021 Mar 9;eabg8663. DOI:https://doi.org/10.1126/science.abg8663.
- Saad-Roy CM, Wagner CE, Baker RE, et al. Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years. Science. 2020;370:811–818.
- Wise J. Covid-19: new data on Oxford candi vaccine backs 12 week dosing interval. BMJ. 2021;372:n326.
- Baraniuk C. Covid-19: how the UK vaccine rollout delivered success, so far. BMJ. 2021;372:n421.
- Rh S, Stuart A, Greenland M, et al. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397:2043–2046.
- [cited 2021 Mar 31]. Available from: https://clinicaltrials.gov/ct2/show/NCT04684446?term=COVID-19+Heterologous+Prime+Boost+study&draw=2&rank=2
- Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021 Apr 6. DOI:https://doi.org/10.1056/NEJMc2103916.
- Khoury DS, Cromer D, Reynaldi A, et al. What level of neutralising antibody protects from COVID-19? medRxiv. 2021;2021(3):09.21252641.
- Tauzin A, Nayrac M, Benlarbi M. et al. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. bioRxiv. Mar 2021. 18;2021.03.18.435972. Doi: https://doi.org/10.1101/2021.03.18.435972
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 2020;383:1920–1931.
- Jarjour NN, Masopust D, Jameson SC. T cell memory: understanding COVID-19. Immunity. 2021;54:14–18.
- Cox RJ, Brokstad KA. Not just antibodies: b cells and T cells mediate immunity to COVID-19. Nat Rev Immunol. 2020t;20:581–582.
- Walensky RP, Walke HT. Fauci AS. SARS-CoV-2 variants of concern in the United States-challenges and opportunities. JAMA. 2021 Mar 16;325(11):1037–1038.
- Collier DA, De Marco A, Ferreira I, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021 Mar 11. DOI:https://doi.org/10.1038/s41586-021-03412-7.
- Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021 Feb 10. DOI:https://doi.org/10.1038/s41586-021-03324-6.
- Edara VV, Hudson WH, Xie X, et al. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. JAMA. 2021 Mar 19. DOI:https://doi.org/10.1001/jama.2021.4388.
- Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–1362.
- Rubin R. COVID-19 Vaccines vs variants—determining how much immunity is enough. JAMA. 2021;325:123–1241.
- Shinde V, Bhikha S, Hoosain Z, et al. Preliminary efficacy of the NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. medRxiv. 2021;384(20):1899–1909. DOI: https://doi.org/10.1056/NEJMoa2103055.
- Yadav PD, Sapkal GN, Abraham P, et al. Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clin Infect Dis. 2021 May;ciab411. 7. doi:https://doi.org/10.1093/cid/ciab411
- Kuehn BM. High-Income countries have secured the bulk of COVID-19 vaccines. JAMA. 2021;325:612.
- Meyer MN, Gjorgjieva T, Rosica D. Trends in health care worker intentions to receive a COVID-19 vaccine and reasons for hesitancy. JAMA Network Open. 2021;4:e215344.
- Lazarus JV, Ratzan SC, Palayew A, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27:225–228.
- Latkin C, Dayton LA, Yi G, et al. COVID-19 vaccine intentions in the United States, a social-ecological framework. Vaccine. 2021 Mar. DOI:https://doi.org/10.1016/j.vaccine.2021.02.058.
- Grunbach KJT, Desai M, et al. Association of race/ethnicity with likeliness of COVID-19 vaccine uptake among health workers and the general population in the San Francisco Bay area. JAMA Intern Med. 2021 March 30;e211445. DOI:https://doi.org/10.1001/jamainternmed20211445
- Britton T, Ball F, Trapman P. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. Science. 2020;369:846–849.
- Frenck RW Jr, Klein NP, Kitchin N, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;May27 https://doi.org/10.1056/NEJMoa2107456
- Adhikari EH, Spong CY. COVID-19 vaccination in pregnant and lactating women. JAMA. 2021;325:1039–1040.
- Rasmussen SA, Kelley CF, Horton JP, et al. Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know. Obstet Gynecol. 2021;137:408–414.
- Gostin LO, Cohen GI, Shaw J. Digital health passes in the age of COVID-19: are “Vaccine Passports” lawful and ethical? JAMA. 2021 Apr 7. https://doi.org/10.1001/jama.2021.5283.
- Wells R, Galvani AP. The interplay between COVID-19 restrictions and vaccination. Lancet Infect Dis. 2021 Mar;8–74. https://doi.org/10.1016/S1473-3099(21